Delayed Puberty
Conditions
Keywords
Delayed Puberty, Boys, Hormones, Polymorphism, Genetic
Brief summary
To evaluate the phenotype and biochemical characteristics of boys referred for delayed puberty, to describe the frequency of associated co-morbidities and diseases, to evaluate the diagnostic criteria and the effect of testosterone treatment.
Detailed description
Delayed Puberty in Boys; Clinical and biochemical characteristics and effect of testosterone treatment, is a retrospective study in a large case series of Danish boys with delayed puberty. All boys were referred to the Department of Growth and Reproduction to be evaluated for delayed puberty. Medical history: Birth length, birth weight, gestational age at birth, medical history (including cryptorchidism and hypospadias), family history of delayed puberty in mother, father and possible siblings. Physical examination: Pubertal staging according to Tanners classification of boys, genitalia development (G1-G5), pubic hair development (PH1-PH6), axillary hair (yes/no), axillary sweat (yes/no), gynecomastia (yes/no), micropenis (yes/no), height, mother height, father height, target height, weight, BMI, bone age and predicted adult height. Blood sampling for measurement of hormone levels: Follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol, anti-mullerian hormone, sex hormone-binding globulin, testosterone, dehydroepiandrosterone-sulfate, androstenedione, inhibin A, inhibin B, growth hormone, insulin like growth factor-1 and insulin like growth factor binding protein-3. Gonadotropin-releasing hormone stimulation test for measurement of peak FSH and peak LH. Retrospective DNA analysis looking for common polymorphisms. If testosterone treatment were initiated, route of administration, dose and duration of treatment were registered.
Interventions
Sponsors
Rigshospitalet, Denmark
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
13 Years to 20 Years
Healthy volunteers
No
Inclusion criteria
* All boys identified in the period from January 1990 to February 2013
Exclusion criteria
* Misclassified (other diagnoses) * Insufficient data * Lost to follow up
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Age at diagnosis in boys with delayed puberty. | At first evaluation | We will evaluate the mean age at diagnosis as well as the age distribution of newly diagnosed boys. These data are compared to age at onset and progression of normal puberty in contemporary healthy Danish boys. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Selected secondary outcomes include clinical, auxological and biochemical parameters and association to specific genetic polymorphisms | At first evaluation and during first 12 months of observation / treatment | Specifically, genital stage, pubic hair stage, axillary hair, axillary sweat, gynecomastia, micropenis, height, mother height, father height, target height, weight, BMI, bone age and predicted adult height. We will evaluate serum levels of follicle stimulating hormone, luteinizing hormone, estradiol, anti-mullerian hormone, sex hormone-binding globulin, testosterone, dehydroepiandrosterone-sulfate, androstenedione, inhibin A, inhibin B, growth hormone, insulin like growth factor-1 and insulin like growth factor binding protein-3. We will evaluate the effect of candidate polymorphisms suspected to affect pubertal timing, e.g. FSHR, FSHB, FGF23, KISS1, NeurokininB, GnRH, GnRH-R, LH, LH-R, GHRd3. |
Countries
Denmark
Outcome results
None listed